IP Library Patent Application 17618254
Patent Application
App. No. 17/618,254

PRODUCTION OF FUCOSYLATED OLIGOSACCHARIDES IN BACILLUS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/618,254
Abstract

Disclosed are non-sporulating Bacillus cells for the production of a fucosylated oligosaccharide as well as a method for producing a fucosylated oligosaccharide, wherein said Bacillus cell has been genetically engineered to possess a lactose permease, a GDP-fucose biosynthesis pathway and a fucosyltransferase.

Claims (18)

1 . A non-sporulating Bacillus cell for the production of a fucosylated oligosaccharide, wherein said cell has been genetically engineered to possess a lactose permease, a GDP-fucose biosynthesis pathway and a fucosyltransferase.

2 . The Bacillus cell according to claim 1 , wherein the sporulation has been impaired by deletion or functional inactivation of one or more of the genes encoding Spo0A, sigma E and sigma F.

3 . The Bacillus cell according to claim 1 , wherein the lactose permease is E. coli LacY or a functional variant thereof.

4 . The Bacillus cell according to claim 1 , wherein the GDP-fucose biosynthesis pathway is a de novo GDP-fucose biosynthesis pathway and/or a salvage pathway.

5 . The Bacillus cell according to claim 1 , wherein the fucosyltransferase is a lactose-accepting fucosyltransferase, optionally a fucosyltransferase selected from the group of α-1,2-fucosyltransferases and α-1,3-fucosoyltransferases.

6 . The Bacillus cell according to claim 1 , wherein said Bacillus cell lacks any β-galactosidase activity or possesses reduced β-galactosidase activity as compared to a wild-type progenitor Bacillus cell of the same species.

7 . The Bacillus cell according to claim 6 , wherein the Bacillus cell has been genetically engineered by deletion or functional inactivation of at least one of the genes selected from the group consisting of yesZ and ganA.

8 . The Bacillus cell according to claim 1 , wherein said Bacillus cell is a Bacillus subtilis cell.

9 . A product comprising a Bacillus cell according to claim 1 for production of a fucosylated oligosaccharide.

10 . A method for production of a fucosylated oligosaccharide, comprising

providing a non-sporulating Bacillus cell as defined in claim 1 ;

cultivating said Bacillus cell in a medium and under conditions that are permissive for production of a fucosylated oligosaccharide; and optionally

retrieving the fucosylated oligosaccharide from the medium and/or the Bacillus cell.

11 . The method according to claim 10 , wherein the medium comprises lactose.

12 . The method according to claim 10 , wherein the medium comprises L-fucose.

13 . A fucosylated oligosaccharide produced by a method according to claim 10 .

14 . A product comprising a fucosylated oligosaccharide according to claim 13 for manufacture of a nutritional composition, optionally of an infant formula.

15 . A nutritional composition comprising a fucosylated oligosaccharide according to claim 13 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2024
From: JENNEWEIN, STEFAN; WARTENBERG, DIRK; HABERSETZER, STEFANIE
To: CHR HANSEN HMO GMBH
Reel/Frame 066860/0721 →